Watanabe T | Hematology Division National Cancer Center Hospital

スポンサーリンク

概要

関連著者

もっと見る

著作論文

Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma
Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan
Primary Hepatic Low-Grade B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Type : A Case Report and Review of the Literature
Japanese phase II study of ^Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma
Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer : Japan Clinical Oncology Group study, JCOG 9208
Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma
CD44 Variant Isoform Expression and Breast Cancer Prognosis
Concordance in Pathological Response to Neoadjuvant Chemotherapy between Invasive and Noninvasive Components of Primary Breast Carcinomas
Two Special Types of Breast Cancer Presenting as Progressive Disease after Neoadjuvant Chemotherapy with Docetaxel plus Doxorubicin
Evaluation of Histopathological Criteria for Identifying Node-negative Breast Cancer with High Risk of Early Recurrence in the NSAS-BC Protocol Study
Seven Cases of Breast Cancer Recurrence Limited to the Central Nervous System without Other Visceral Metastases
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma
Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma
Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab
Tumor-associated Fever in Recurrent Breast Cancer with Liver Metastases

もっと見る

スポンサーリンク